- R esults from phase II investigations of atacicept in systemic lupus erythematosus (Abstract Numbers: 12L and 764)
Presentation Session Title Lead Author Abstract ID Date / Time Type/Title Late-Breaking Poster Presentation Efficacy and Safety of Dr. Joan T. Abstract ID: Sunday, Late-breaking Atacicept in Patients Merrill, 12 L November 13 Abstract Session/ with Systemic Lupus Oklahoma, 9:00 - 11:00 Late-breaking Erythematosus: Results Medical Research AM ET Poster Session of a 24-Week Foundation, Presentation Randomized, Oklahoma Time: Tuesday, Placebo-Controlled, City, OK, November 15, Phase IIb Study U.S. 9:00 - 11:00 AM ET Poster Presentation Atacicept: Integrated Dr. Patricia Abstract ID: Sunday, Poster Session A/ Safety Profile from Fraser, 764 November 13, Systemic Lupus Phase II Randomized EMD Serono 9:00 - 11:00 Erythematosus - Placebo-Controlled Billerica, AM ET Clinical Aspects Studies in Autoimmune MA, U.S. and Treatment - Diseases Poster Session I: Clinical Trial Design and Current TherapiesFor more information about the data to be presented, please review the ACR/ARHP website. Also, visit Merck KGaA, Darmstadt, Germany's booth at this year's Annual Meeting to learn more about the company's commitment to advancing innovation in lupus and other immunological diseases. About Atacicept Atacicept is a potential treatment for systemic lupus erythematosus (SLE). Atacicept, a recombinant fusion protein, contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL. These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases such as SLE. Atacicept has been shown in animal models to affect several stages of B-cell development and may inhibit the survival of cells responsible for making antibodies. Merck KGaA, Darmstadt, Germany, acquired exclusive worldwide development and commercialization rights for atacicept, including in North America, from Zymogenetics in 2008. Atacicept is currently under clinical investigation and not approved for any use in the United States, Canada and Europe. About Systemic Lupus Erythematosus (SLE) Lupus is a chronic inflammatory disease, where the immune system attacks the body's own tissues and organs. Systemic lupus erythematosus (SLE) is the most common form of lupus and can result in swollen, painful joints, skin rash, extreme fatigue and kidney damage. Estimates vary widely, but SLE may affect as many 300,000 patients in the U.S. alone. Women and individuals with African, Asian, and Hispanic heritage are affected disproportionately by SLE.